Savara, Inc. (SVRA)

[lux1]

half of the shares offered were already bought by Zambon Pharma: 4.693 M shares that is the the 19.9% of the Savara outstanding shares.
Zanbon is an Italian private Co,with 2800 employees and with sales in Europe , Asia, China, South America but not US, then a perfect commercial partner for the non-US markets. They are also involved in Cystic Fibrosis and respiratory diseases.

IMO a merger could be possible as a medium-term target, likely after Molgradex results and Aerovanc results or interim results.
I hope a merger for a worldwide, multi billions combined company next year.
20% could be a down payment for future agreements.

http://www.zambonpharma.com/en/

http://www.zambonpharma.com/en/therapeutic-areas/rare-diseases/